The secondary end points were (1) change from baseline in other liver enzymes including alanine transaminase (ALT) and aspartate transaminase (AST) postbiologic therapy, (2) change from baseline in markers of IBD activity including the proportion of patients with colitis who achieved endoscopic and clinical response (improvement) or remission, (3) adverse events (AEs) leading to discontinuation of biologics or loss of response to biologics and, (4) proportion of patients who developed liver-related events during the follow-up period. This evidence concerns the gene GPT and colitis.